TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25923229

Group type: EXPERIMENTAL
Intervention: Sequential therapy (rabeprazole 20 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by rabeprazole 20 mg twice daily, tinidazole 500 mg twice daily plus clarithromycin 500 mg twice daily for another 5 days)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Modified bismuth-included quadruple therapy (rabeprazole 20 mg twice daily, levofloxacin hydrochloride 400 mg twice daily, clarithromycin 500 mg twice daily, and colloidal bismuth pectin 200 mg 3 times a day for 7 days)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Both groups (sequential therapy and modified bismuth-included quadruple therapy)
Number of subjects: 199
Study: 24435939

Group type: EXPERIMENTAL
Intervention: Fear-Factor Stress Test (FFST)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (placebo version of FFST)
Number of subjects: 90
Study: 23203360

Group type: EXPERIMENTAL
Intervention: Peer-led recovery group (Vet-to-Vet)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Clinician-led recovery group
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Group attendance
Number of subjects: 240
Study: 19529955

Group type: EXPERIMENTAL
Intervention: Ultrasonography combined with BIJV‐IOPTH
Number of subjects: 78

Group type: COMPARATOR
Intervention: Ultrasonography alone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: BIJV‐IOPTH
Number of subjects: 78

Group type: COMPARATOR
Intervention: Open neck explorations (unilateral)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Open neck explorations (bilateral)
Number of subjects: 78
Study: 17310303

Group type: EXPERIMENTAL
Intervention: Parecoxib (40 mg, administered twice within 12 h)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Propacetamol (2 g, administered twice within 12 h)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Parecoxib
Number of subjects: 182

Group type: COMPARATOR
Intervention: Propacetamol
Number of subjects: 182
Study: 15362796

Group type: COMPARATOR
Intervention: Proton pump inhibitor (group III)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: H2-receptor antagonist (group II)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: No treatment (group I)
Number of subjects: 102
Study: 11219482

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30 mg
Number of subjects: 71

Group type: COMPARATOR
Intervention: Nifedipine GITS 20 mg
Number of subjects: 71
Study: 9886530

Group type: EXPERIMENTAL
Intervention: Day 3 transfer of cleavage stage embryos (3.7 embryos transferred)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Day 5 transfer of blastocysts (2.2 embryos transferred)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Transfer of 2 blastocysts
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Transfer of 3 blastocysts
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Blastocyst culture and transfer
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Thaw and transfer of cryopreserved blastocysts
Number of subjects: 100
Study: 9013242

Group type: EXPERIMENTAL
Intervention: HEPA respirator
Number of subjects: 0

Group type: COMPARATOR
Intervention: N-95 masks
Number of subjects: 0
Study: 2697728

Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg once a day (o.d.)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg once a day (o.d.)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg twice a day (b.i.d.)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg twice a day (b.i.d.)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg o.d.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg o.d.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg b.i.d.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg b.i.d.
Number of subjects: 25
Study: 11424

Group type: EXPERIMENTAL
Intervention: Parsalmide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 20
Study: 30874716

Group type: EXPERIMENTAL
Intervention: Catheter ablation (n=1108)
Number of subjects: 2204

Group type: COMPARATOR
Intervention: Drug therapy (n=1096)
Number of subjects: 2204
Study: 29953782

Group type: EXPERIMENTAL
Intervention: Intraperitoneal combined with intravenous neoadjuvant chemotherapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Cytoreductive surgery and six to eight courses of intravenous chemotherapy
Number of subjects: 108
Study: 26346592

Group type: EXPERIMENTAL
Intervention: Vortioxetine 5 mg
Number of subjects: 2155

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 2155

Group type: EXPERIMENTAL
Intervention: Vortioxetine 15 mg
Number of subjects: 2155

Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg
Number of subjects: 2155

Group type: EXPERIMENTAL
Intervention: Vortioxetine 5 mg (elderly patients)
Number of subjects: 2155

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 2155
Study: 23187038

Group type: EXPERIMENTAL
Intervention: Locked one-third tubular bridge plating
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard one-third tubular bridge plating
Number of subjects: 8
Study: 21530937

Group type: EXPERIMENTAL
Intervention: Left Radial Approach (LRA)
Number of subjects: 1540

Group type: COMPARATOR
Intervention: Right Radial Approach (RRA)
Number of subjects: 1540

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 1540
Study: 19082404

Group type: EXPERIMENTAL
Intervention: 25 x 0.70 mm needle
Number of subjects: 54

Group type: COMPARATOR
Intervention: 20 x 0.55 mm needle
Number of subjects: 54
Study: 16856900

Group type: EXPERIMENTAL
Intervention: Full-mouth ultrasonic debridement (UD)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Quadrant-wise scaling and root planing (Q-SRP)
Number of subjects: 37
Study: 12767084

Group type: EXPERIMENTAL
Intervention: Recommendations about screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recommendations plus tailored discussion (on beliefs, feelings, costs, and access)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No message (control group)
Number of subjects: 0
Study: 11127214

Group type: EXPERIMENTAL
Intervention: Etidronate for 56 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo for 56 weeks
Number of subjects: 98
Study: 9303505

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b for 6 months
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b for 12 months
Number of subjects: 211
Study: 8285939

Group type: EXPERIMENTAL
Intervention: Goldmann keratometry performed by a single masked observer
Number of subjects: 71

Group type: COMPARATOR
Intervention: Javal‐Schiotz Keratometry performed by an independent observer
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Goldmann keratometry
Number of subjects: 71
Study: 2943781

Group type: EXPERIMENTAL
Intervention: Emergency angioplasty
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intracoronary streptokinase
Number of subjects: 28
Study: 30157357

Group type: EXPERIMENTAL
Intervention: L-carnitine combined with coenzyme Q10
Number of subjects: 262

Group type: COMPARATOR
Intervention: Vitamin B1 (placebo control)
Number of subjects: 262
Study: 26864193

Group type: EXPERIMENTAL
Intervention: IP ketorolac 30 mg + intravenous saline
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 30 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intraperitoneal saline + intravenous saline
Number of subjects: 120
Study: 24827696

Group type: EXPERIMENTAL
Intervention: Peripheral nerve block (PNB) - femoral nerve block and sciatic nerve block
Number of subjects: 210

Group type: COMPARATOR
Intervention: Periarticular injection analgesia (PAI) - mixture of ropivacaine, saline, epinephrine, morphine hydrochloride, and dexamethasone
Number of subjects: 210

Group type: COMPARATOR
Intervention: Both groups (PNB and PAI)
Number of subjects: 210
Study: 22495621

Group type: EXPERIMENTAL
Intervention: Lu AA21004 (5 or 10mg/day)
Number of subjects: 639

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Lu AA21004 (double-blind)
Number of subjects: 639

Group type: COMPARATOR
Intervention: Placebo (double-blind)
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Lu AA21004 (open-label)
Number of subjects: 639
Study: 20828380

Group type: EXPERIMENTAL
Intervention: Modified surgical approach with separate suturing of internal and external anal sphincter muscles using monofilament absorbable sutures
Number of subjects: 26

Group type: COMPARATOR
Intervention: Historical control group of women with prior OASI (n = 180)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Historical control group of primiparous women delivered vaginally without a diagnosis of OASI (n = 100)
Number of subjects: 26
Study: 17698323

Group type: EXPERIMENTAL
Intervention: First Rank Symptoms (FRSs) present at baseline
Number of subjects: 388

Group type: COMPARATOR
Intervention: No First Rank Symptoms (FRSs) at baseline
Number of subjects: 388
Study: 16135141

Group type: EXPERIMENTAL
Intervention: UVB311 nm therapy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Calcipotriol with UVB311 nm
Number of subjects: 9

Group type: COMPARATOR
Intervention: Broad-band UVB therapy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Quality of life (DLQI score)
Number of subjects: 9
Study: 12192323

Group type: EXPERIMENTAL
Intervention: Specialized amino acid mixture (14 g arginine, 3 g HMB, 14 g glutamine)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (isonitrogenous, isocaloric supplementation of nonessential amino acids)
Number of subjects: 35
Study: 10201863

Group type: EXPERIMENTAL
Intervention: Modified isotonic SELG preparation with 7.5 g/l of magnesium sulphate (SELG-Mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard isotonic PEG‐ELS (SELG)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (SELG and SELG-Mg)
Number of subjects: 120
Study: 7828294

Group type: EXPERIMENTAL
Intervention: Nadolol (20 mg/d)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nadolol (40 mg/d)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atenolol (25 mg/d)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg/d)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2388639

Group type: EXPERIMENTAL
Intervention: Piracetam (3.2 g for 12 weeks, increased to 4.8 g for an additional 12 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (identical amount for 12 weeks)
Number of subjects: 20
Study: 30106956

Group type: EXPERIMENTAL
Intervention: Continuation of mass azithromycin distribution (annual or twice yearly)
Number of subjects: 3938

Group type: COMPARATOR
Intervention: Discontinuation of mass azithromycin distribution
Number of subjects: 3938

Group type: COMPARATOR
Intervention: Comparison of continuation vs discontinuation
Number of subjects: 3938
Study: 27769775

Group type: EXPERIMENTAL
Intervention: With-stylet technique
Number of subjects: 121

Group type: COMPARATOR
Intervention: Without-stylet technique
Number of subjects: 121
Study: 25766941

Group type: EXPERIMENTAL
Intervention: Complete revascularization
Number of subjects: 296

Group type: COMPARATOR
Intervention: IRA-only revascularization
Number of subjects: 296
Study: 22986466

Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study: 21637969

Group type: EXPERIMENTAL
Intervention: Azelnidipine (8-16 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine (2.5-5 mg/day)
Number of subjects: 0
Study: 19675101

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (62% ALA, 5.4 g/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 36
Study: 16967643

Group type: EXPERIMENTAL
Intervention: Faustlos program
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study: 15382590

Group type: EXPERIMENTAL
Intervention: Manipulative therapy (French method of R. Meigne)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional physical therapy
Number of subjects: 80
Study: 11113956

Group type: EXPERIMENTAL
Intervention: Non-parametric bootstrap methods for comparing arithmetic mean costs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard parametric methods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomization test
Number of subjects: 0
Study: 9039073

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 902

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 902
Study: 8100628

Group type: EXPERIMENTAL
Intervention: Low-volume whole bowel irrigation (WBI)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Syrup of ipecac 30 ml followed by activated charcoal 50 g in sorbitol
Number of subjects: 6
Study: 3826687

Group type: EXPERIMENTAL
Intervention: Sevoflurane and oxygen
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sevoflurane, oxygen, and nitrous oxide (63.5% end-tidal nitrous oxide)
Number of subjects: 40
Study: 30892108

Group type: EXPERIMENTAL
Intervention: Cholestyramine 15% Ointment applied twice a day for 2 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo Ointment applied twice a day for 2 months
Number of subjects: 30
Study: 30322012

Group type: EXPERIMENTAL
Intervention: AHA dietary counselling
Number of subjects: 119
Study: 27664296

Group type: COMPARATOR
Intervention: 2mA anodal stimulation
Number of subjects: 150

Group type: COMPARATOR
Intervention: 2mA cathodal stimulation
Number of subjects: 150

Group type: COMPARATOR
Intervention: 1mA anodal stimulation
Number of subjects: 150

Group type: COMPARATOR
Intervention: 1mA cathodal stimulation
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 150
Study: 24103486

Group type: EXPERIMENTAL
Intervention: RASS+BIS (BIS-augmented sedation)
Number of subjects: 300

Group type: COMPARATOR
Intervention: RASS (control group)
Number of subjects: 300
Study: 22700888

Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg twice daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 25
Study: 20683945

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Number of subjects: 107

Group type: COMPARATOR
Intervention: peginterferon alfa-2a and ribavirin
Number of subjects: 107
Study: 18036277

Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Monopolar electrocautery
Number of subjects: 60
Study: 17013444

Group type: EXPERIMENTAL
Intervention: Peg‐IFN ‐2b 3.0 mcg/kg QW x 12 weeks followed by 1.5 mcg/kg QW x 36 weeks plus 800‐1200 mg ribavirin (Arm A)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Peg‐IFNalpha‐2b 1.5 mcg/kg QW x 48 weeks plus 800‐1200 mg ribavirin (Arm B)
Number of subjects: 188
Study: 15297106

Group type: EXPERIMENTAL
Intervention: High fat oral supplement (70:25:5 fat:carbohydrate:protein)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High carbohydrate oral supplement (25:70:5 fat:carbohydrate:protein)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High fat and high carbohydrate supplements
Number of subjects: 16
Study: 11296329

Group type: EXPERIMENTAL
Intervention: Dopexamine infusion at 2 microg/kg per minute (n = 12)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (0.9% saline) (n = 18)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dopexamine infusion
Number of subjects: 30
Study: 9308523

Group type: EXPERIMENTAL
Intervention: Ligament reconstruction with tendon interposition (Group I)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ligament reconstruction alone (Group II)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 8115101

Group type: EXPERIMENTAL
Intervention: Peribulbar anesthesia with prilocaine 3% with felypressin and hyaluronidase
Number of subjects: 87

Group type: COMPARATOR
Intervention: Retrobulbar anesthesia with prilocaine 3% with felypressin and hyaluronidase
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both groups (Peribulbar and Retrobulbar)
Number of subjects: 87
Study: 3554493

Group type: EXPERIMENTAL
Intervention: Gastric bypass (n = 29)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Gastroplasty (n = 28)
Number of subjects: 57
Study: 30538163

Group type: EXPERIMENTAL
Intervention: CPAP (Continuous Positive Airway Pressure) use averaged 2.9±2.3 hours per night, with 21% fully adherent (at least 4 hours use on 5 days per week).
Number of subjects: 149

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 149
Study: 28891908

Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg twice daily
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 25749499

Group type: EXPERIMENTAL
Intervention: Graded activity (moderate intensity treadmill walking, brief education and strength exercises)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Physiotherapy (strengthening, stretching and motor control)
Number of subjects: 66
Study: 23307542

Group type: EXPERIMENTAL
Intervention: Tacrolimus plus clotrimazole troche
Number of subjects: 6

Group type: COMPARATOR
Intervention: Tacrolimus plus nystatin suspension
Number of subjects: 6
Study: 20947382

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia with levobupivacaine for 6 postoperative days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Patient-controlled intravenous morphine starting on the 3rd postoperative day
Number of subjects: 50
Study: 19858400

Group type: EXPERIMENTAL
Intervention: Lapatinib plus paclitaxel
Number of subjects: 579

Group type: COMPARATOR
Intervention: Placebo plus paclitaxel
Number of subjects: 579
Study: 16913262

Group type: EXPERIMENTAL
Intervention: Olopatadine HCl nasal spray 0.6%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olopatadine HCl nasal spray 0.4%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 0
Study: 15096077

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enteric-coated fluoxetine 90 mg once weekly
Number of subjects: 0
Study: 11237915

Group type: EXPERIMENTAL
Intervention: AAION
Number of subjects: 301

Group type: COMPARATOR
Intervention: NAION
Number of subjects: 301
Study: 9272343

Group type: EXPERIMENTAL
Intervention: Various pertussis vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laboratory-confirmed B. pertussis infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not-confirmed cases
Number of subjects: 0
Study: 7705377

Group type: EXPERIMENTAL
Intervention: Maximal upright bicycle exercise
Number of subjects: 6
Study: 3675257

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 57
Study: 29253089

Group type: EXPERIMENTAL
Intervention: High-Dose Influenza Vaccine (FluzoneHD, Sanofi)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Standard-Dose Influenza Vaccine (Fluviral, GSK)
Number of subjects: 172
Study: 27599620

Group type: EXPERIMENTAL
Intervention: Feedback Game (FG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No Feedback (NF)
Number of subjects: 50
Study: 24459138

Group type: EXPERIMENTAL
Intervention: Enoxaparin with HeprAN membrane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enoxaparin with polysulphone (PS) membrane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: No enoxaparin with HeprAN membrane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: No enoxaparin with polysulphone (PS) membrane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: No enoxaparin with bubble trap
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enoxaparin with bubble trap
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Polysulphone membrane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HeprAN membrane
Number of subjects: 10
Study: 22918177

Group type: EXPERIMENTAL
Intervention: High-protein (HP) nutrition bar (280 kcal)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High-carbohydrate (HC) nutrition bar (260 kcal)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Non-intervention day (control)
Number of subjects: 54
Study: 20526620

Group type: EXPERIMENTAL
Intervention: Lightweight mesh fixed by fibrin glue
Number of subjects: 276

Group type: COMPARATOR
Intervention: Clip fixation
Number of subjects: 276
Study: 18770962

Group type: EXPERIMENTAL
Intervention: Abdominal surgical approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transvaginal surgical approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic and other transvaginal minimal access techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suspension of the vaginal apex to the uterosacral ligaments or sacrospinous ligaments
Number of subjects: 0
Study: 15880023

Group type: EXPERIMENTAL
Intervention: Everolimus 0.75-1.5 mg bid plus reduced-exposure cyclosporine (CsA) and prednisone
Number of subjects: 2

Group type: COMPARATOR
Intervention: Reduced-exposure cyclosporine (CsA)
Number of subjects: 2
Study: 12718222

Group type: EXPERIMENTAL
Intervention: Allicor (600 mg/day)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Allicor (300 mg/day)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214

Group type: COMPARATOR
Intervention: Benzimidazole
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Allicor
Number of subjects: 214
Study: 10469713

Group type: EXPERIMENTAL
Intervention: 100 mg/day danazol for 6 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 28
Study: 8737436

Group type: EXPERIMENTAL
Intervention: Interactional Group Discussion (IGD)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (no IGD)
Number of subjects: 144